Plain-English translation of NCT06863233 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Lung Cancer research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This research study is testing whether a special type of PET scan using an imaging agent called can safely and accurately identify certain immune cells (called CD8+ T cells) in people with advanced lung cancer. These immune cells are important because they help fight cancer, and this new imaging technique could help doctors see how well the treatment is working.
Doctors need better ways to track whether immune cell treatments are actually reaching the cancer and doing their job. This imaging scan could help them see inside the body in real time, which might improve how they monitor and adjust treatment for lung cancer patients.
You would receive the special PET imaging scan using the new imaging agent to see how your immune cells respond to treatment. The study involves a small group of five people with advanced lung cancer who are already enrolled in a separate cell therapy trial. Your participation would help researchers understand whether this new imaging technique can safely track immune cells and predict how well the treatment works.
AI-generated summary from trial data · Aug 24, 2026 · Not medical advice
United States